You know what it is like to be a bat. To be a bat is to be a mammal like no other. You spend half the day dozing in caves, and then you all leave together. You flap about, in order to get anywhere. You find out where you are by seeing how the sounds you make come back to you. You are where all the others are. Each of you is there because everyone else is there. Everyone else is a bit batty. You know what it is like to be a bat.
Sunday, February 21, 2021
Tuesday, February 16, 2021
Health and Safety
"Police officers are, quite rightly, furious at the government for failing to prioritise them in the vaccination schedule."
Click on that quote for more on that "quite rightly,"
Blaming the government is how our democracy works; but I was wondering, who failed to get the police vaccinated in the early days of this pandemic, when it would have done them (and therefore us) much more good?
Many months ago (here is a link to one timeline) the vaccines were safe enough to be given to thousands of volunteers, for phases II and III of the testing process (for a description of those phases see the quote below, which is cut-and-pasted from WHO). Could some of the vaccines not have been made available then, for key workers who volunteered (for the vaccines, not for participation in the trials, which were presumably randomized)? Tinkering with the timetable of the current roll-out of mass vaccinations would inevitably involve some risk to that roll-out. Why do people who failed to think this through earlier, when it would have done more good, now think that they know better than the government how to balance those risks?
Here is that WHO quote:
"An experimental vaccine is first tested in animals to evaluate its safety and potential to prevent disease. It is then tested in human clinical trials, in three phases:
In phase I, the vaccine is given to a small number of volunteers to assess its safety, confirm it generates an immune response, and determine the right dosage.
In phase II, the vaccine is usually given [to] hundreds of volunteers, who are closely monitored for any side effects, to further assess its ability to generate an immune response. In this phase, data are also collected whenever possible on disease outcomes, but usually not in large enough numbers to have a clear picture of the effect of the vaccine on disease. Participants in this phase have the same characteristics (such as age and sex) as the people for whom the vaccine is intended. In this phase, some volunteers receive the vaccine and others do not, which allows comparisons to be made and conclusions drawn about the vaccine.
In phase III, the vaccine is given to thousands of volunteers – some of whom receive the investigational vaccine, and some of whom do not, just like in phase II trials. Data from both groups is carefully compared to see if the vaccine is safe and effective against the disease it is designed to protect against."